Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions
Acute Myeloid Leukemia Refractory
Interventions
DRUG

NP137

IV infusion, 14mg/kg or 9mg/kg, every 2 weeks

DRUG

Azacitidine Injection

Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)

DRUG

Venetoclax

Orally, 70 mg, every day on Days 1-28

Trial Locations (1)

69008

Centre Léon Bérard, Lyon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NETRIS Pharma

INDUSTRY

lead

Centre Leon Berard

OTHER

NCT06150040 - Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | Biotech Hunter | Biotech Hunter